[{"NetIncomeLossConverted_1_Q2_USD":-31167000.0,"NetIncomeLossConverted_2_Q2_USD":-108407000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-59048000.0,"CommonStockSharesOutstanding_0_Q2_shares":117727086.0,"StockholdersEquity_0_Q2_USD":563779000.0,"EarningsPerShareBasic_1_Q2_USD":-0.27,"EarningsPerShareBasic_2_Q2_USD":-0.97,"Assets_0_Q2_USD":672238000.0,"CommonStockSharesConverted_0_Q2_shares":117727086.0,"RevenuesConverted_1_Q2_USD":66988000.0,"RevenuesConverted_2_Q2_USD":72706000.0,"Ticker":"VIR","CIK":"1706431","name":"VIR BIOTECHNOLOGY, INC.","OfficialName":"Vir Biotechnology Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"3076942595.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200811"}]